NP137R

NP137R is a discovery-stage therapeutic candidate being developed by NETRIS Pharma. It is a derivative or specific application of NP137, a humanized monoclonal antibody that targets Netrin-1. Netrin-1 is a secreted protein often overexpressed in various cancers, where it acts as a survival factor by blocking apoptosis mediated by its dependence receptors, such as DCC and UNC5H. By targeting Netrin-1, NP137R aims to restore apoptosis in cancer cells. NP137R is specifically designed for use in radiotherapy, likely as a radiopharmaceutical (radioimmunotherapy) or a radiosensitizer, to treat Netrin-1 expressing malignancies.